Target Name: LOC102724023
NCBI ID: G102724023
Other Name(s): Glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial isoform 1 | GAL3B_HUMAN | GATD3B | keio novel protein-I | glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial | LOC102724023 variant 1 | Protein HES1 | Glutamine amidotransferase like class 1 domain containing 3B | Keio novel protein-I | Glutamine amidotransferase class 1 domain containing 3B, transcript variant 1 | Protein GT335 | KNP-I | Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial | glutamine amidotransferase like class 1 domain containing 3B | glutamine amidotransferase class 1 domain containing 3B | ES1 protein homolog, mitochondrial

LOC102724023: A Potential Drug Target and Biomarker

Exploring the Potential Applications of LOC102724023 (Glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial isoform 1) as a Drug Target or Biomarker

Glutamine amidotransferase-like class 1 domain-containing protein 3B (LOC102724023) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. This protein is a key player in the mitochondrial transport system, which is responsible for transporting essential nutrients, including glutamine, to the mitochondria where they can be used for energy production. The dysfunction of this system has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and metabolic diseases.

Potential Applications of LOC102724023 as a Drug Target

LOC102724023 has been shown to play a crucial role in the regulation of mitochondrial function and metabolism. It is a key player in the transport of glutamine, which is a vital fuel for the mitochondria. The dysfunction of the mitochondrial transport system has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. Therefore, targeting LOC102724023 as a drug could be a promising strategy for treating these diseases.

One of the potential benefits of targeting LOC102724023 is its potential to inhibit its function as a drug target. LOC102724023 has been shown to play a role in the regulation of mitochondrial function and metabolism, which could make it an attractive target for drugs that aim to inhibit its activity. For example, inhibitors of LOC102724023 have been shown to inhibit its activity in cell culture models of neurodegenerative disorders, which could lead to potential therapeutic benefits for treating these disorders.

Another potential benefit of targeting LOC102724023 is its potential to serve as a biomarker for the disease. The dysfunction of the mitochondrial transport system has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. Therefore, measuring the expression of LOC102724023 could be a useful biomarker for these diseases.

Potential Applications of LOC102724023 as a Biomarker

LOC102724023 has also been shown to play a role in the regulation of mitochondrial function and metabolism, which could make it an attractive target for biomarkers that aim to measure the dysfunction of the mitochondrial transport system. For example, LOC102724023 has been shown to be involved in the regulation of mitochondrial function, which could make it an attractive target for biomarkers that aim to measure the dysfunction of the mitochondrial transport system in neurodegenerative disorders.

In addition, LOC102724023 has also been shown to play a role in the regulation of cellular metabolism, which could make it an attractive target for biomarkers that aim to measure the dysfunction of the mitochondrial transport system in diseases that are characterized by cellular metabolism disorders, such as cancer.

Conclusion

LOC102724023 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. Its function as a key player in the

Protein Name: Glutamine Amidotransferase Class 1 Domain Containing 3B

More Common Targets

LOC102724034 | LOC102724036 | LOC102724058 | LOC102724080 | LOC102724081 | LOC102724087 | LOC102724104 | LOC102724122 | LOC102724137 | LOC102724142 | LOC102724145 | LOC102724192 | LOC102724229 | LOC102724288 | LOC102724322 | LOC102724355 | LOC102724428 | LOC102724429 | LOC102724434 | LOC102724438 | LOC102724467 | LOC102724497 | LOC102724511 | LOC102724520 | LOC102724527 | LOC102724528 | LOC102724542 | LOC102724551 | LOC102724572 | LOC102724594 | LOC102724632 | LOC102724642 | LOC102724653 | LOC102724682 | LOC102724684 | LOC102724719 | LOC102724748 | LOC102724761 | LOC102724768 | LOC102724778 | LOC102724785 | LOC102724786 | LOC102724790 | LOC102724802 | LOC102724808 | LOC102724849 | LOC102724889 | LOC102724900 | LOC102724929 | LOC102724934 | LOC102724945 | LOC102724948 | LOC102724968 | LOC102724977 | LOC102725019 | LOC102725030 | LOC102725038 | LOC102725065 | LOC102725112 | LOC102725148 | LOC102725159 | LOC102725238 | LOC103171574 | LOC104054148 | LOC105369160 | LOC105369165 | LOC105369166 | LOC105369167 | LOC105369194 | LOC105369197 | LOC105369209 | LOC105369212 | LOC105369213 | LOC105369250 | LOC105369302 | LOC105369308 | LOC105369309 | LOC105369312 | LOC105369315 | LOC105369325 | LOC105369326 | LOC105369366 | LOC105369367 | LOC105369368 | LOC105369380 | LOC105369384 | LOC105369388 | LOC105369391 | LOC105369395 | LOC105369401 | LOC105369410 | LOC105369441 | LOC105369455 | LOC105369456 | LOC105369464 | LOC105369501 | LOC105369506 | LOC105369513 | LOC105369530 | LOC105369531